Abstract
ACUTE RENAL failure (ARF) has moved to center stage as one of the major renal diseases where there is excellent opportunity and momentum for improved patient care. The high incidence and high mortality rate associated with native kidney ARF remains unchanged, and transplant kidney ARF (“delayed graft function”) is increasing with expanded criteria donors. A major hurdle to designing intervention trials in ARF is the lack of sensitive and specific early diagnostic markers. Ideally, such a marker should differentiate intrinsic ARF (acute tubular necrosis [ATN]) from prerenal ARF, postrenal ARF, and acute glomerulonephritis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
